Gareri P, De Fazio P, Cotroneo A, Lacava R, Gallelli L, De Fazio S, De Sarro G
Clinical Pharmacology Unit and Pharmacovigilance Center, Chair of Pharmacology, Department of Experimental and Clinical Medicine, Faculty of Medicine and Surgery, University Magna Graecia of Catanzaro, Mater Domini University Hospital, Catanzaro, Italy.
Arch Gerontol Geriatr. 2007;44 Suppl 1:199-206. doi: 10.1016/j.archger.2007.01.027.
Drug-induced delirium is a common matter in the elderly and anticholinergics, together with a number of different drugs, may significantly contribute to the delirium onset, especially in demented people. We report a case of a probable anticholinergic drug-induced delirium in an elderly patient. An 80-year-old man with Alzheimer's dementia presented with wandering, depressed mood with crying, somatic worries, anedonism and suicide recurrent ideas. A first external psychiatric assessment led to the diagnosis of melancholic depression and therapy with haloperidol 2mg/day, orphenadrine 100mg daily, amitriptyline 40 mg/day, lorazepam 2mg/day was started. Two weeks later patient suddenly developed delirium, characterized by nocturnal agitation, severe insomnia, daytime sedation, confusion, hallucinations and persecutory delusions. These symptoms progressively worsened, with the consequent caregiver's stress. A geriatric consultation excluded the main causes of delirium, therefore both Operative Units of Pharmacovigilance and Psychiatry were activated, for a clinical pharmacological and psychiatric assessment. Haloperidol, amitriptyline and orphenadrine were promptly dismissed. The patient began a treatment with quetiapine 25mg/day for two days, then twice a day, and infusion of saline 1000 ml/day for two days; psychiatric symptoms gradually diminished and therapy with galantamine was begun. We postulate that this clinical report is suggestive for an anticholinergic drug- induced delirium since the Naranjo probability scale indicated a probable relationship between delirium and drug therapy. In conclusion, a complete geriatric, pharmacological, and psychiatric evaluation might be necessary in order to reduce the adverse drug reactions in older patients treated with many drugs.
药物性谵妄在老年人中很常见,抗胆碱能药物与许多其他药物一起,可能是谵妄发作的重要原因,尤其是在患有痴呆症的人群中。我们报告一例老年患者可能由抗胆碱能药物引起的谵妄病例。一名80岁患有阿尔茨海默病痴呆的男性,表现为徘徊、情绪低落伴哭泣、躯体不适、快感缺失和反复出现自杀念头。首次外部精神科评估诊断为抑郁性抑郁症,并开始使用氟哌啶醇2mg/天、苯海拉明100mg/天、阿米替林40mg/天、劳拉西泮2mg/天进行治疗。两周后,患者突然出现谵妄,表现为夜间躁动、严重失眠、白天嗜睡、意识模糊、幻觉和被害妄想。这些症状逐渐恶化,给护理人员带来了压力。老年病会诊排除了谵妄的主要原因,因此启动了药物警戒和精神科两个业务科室,进行临床药理学和精神科评估。氟哌啶醇、阿米替林和苯海拉明立即停用。患者开始使用喹硫平25mg/天治疗两天,然后改为每天两次,并每天输注1000ml生理盐水两天;精神症状逐渐减轻,并开始使用加兰他敏治疗。我们推测这份临床报告提示为抗胆碱能药物引起的谵妄,因为纳兰霍概率量表表明谵妄与药物治疗之间可能存在关联。总之,为减少接受多种药物治疗的老年患者的药物不良反应,可能需要进行全面的老年病学、药理学和精神科评估。